Santhera Pharmaceuticals Holding AG (0QN1.L)
CHF 9.79
(-0.81%)
CHF 9.79
(-0.81%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 68.84 Million CHF | 197.16% |
| 2022 | -51.97 Million CHF | 8.63% |
| 2021 | -56.88 Million CHF | -7.18% |
| 2020 | -53.07 Million CHF | -408.29% |
| 2019 | -10.44 Million CHF | 79.69% |
| 2018 | -51.42 Million CHF | -1.91% |
| 2017 | -50.45 Million CHF | -52.3% |
| 2016 | -33.12 Million CHF | -1144.03% |
| 2015 | 3.17 Million CHF | 142.21% |
| 2014 | -7.51 Million CHF | -2.85% |
| 2013 | -7.3 Million CHF | 76.54% |
| 2012 | -31.15 Million CHF | -14.49% |
| 2011 | -27.21 Million CHF | -212.4% |
| 2010 | -8.71 Million CHF | 81.3% |
| 2009 | -46.59 Million CHF | -2.19% |
| 2008 | -45.59 Million CHF | -46.47% |
| 2007 | -31.12 Million CHF | -8.69% |
| 2006 | -28.63 Million CHF | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -8.87 Million CHF | 0.0% |
| 2024 Q1 | -8.87 Million CHF | -112.52% |
| 2023 Q2 | -20.34 Million CHF | -100.39% |
| 2023 Q4 | 70.84 Million CHF | 98.37% |
| 2023 FY | 50.5 Million CHF | 197.16% |
| 2023 Q1 | -10.15 Million CHF | 50.04% |
| 2023 Q3 | 35.71 Million CHF | 275.54% |
| 2022 Q3 | -11.16 Million CHF | 56.29% |
| 2022 Q1 | -11.71 Million CHF | 68.91% |
| 2022 Q2 | -25.54 Million CHF | -118.0% |
| 2022 FY | -51.97 Million CHF | 8.63% |
| 2022 Q4 | -20.32 Million CHF | -82.02% |
| 2021 Q2 | -19.44 Million CHF | -99.68% |
| 2021 Q4 | -37.68 Million CHF | -101.48% |
| 2021 FY | -56.88 Million CHF | -7.18% |
| 2021 Q3 | -18.7 Million CHF | 3.81% |
| 2021 Q1 | -9.73 Million CHF | 64.67% |
| 2020 Q2 | -26 Million CHF | -100.84% |
| 2020 Q1 | -12.94 Million CHF | -209.85% |
| 2020 Q4 | -27.56 Million CHF | -102.8% |
| 2020 Q3 | -13.59 Million CHF | 47.73% |
| 2020 FY | -53.07 Million CHF | -408.29% |
| 2019 Q4 | 11.78 Million CHF | 96.56% |
| 2019 Q2 | -22.38 Million CHF | -99.55% |
| 2019 FY | -10.44 Million CHF | 79.69% |
| 2019 Q1 | -11.21 Million CHF | 21.3% |
| 2019 Q3 | 5.99 Million CHF | 126.79% |
| 2018 Q4 | -14.25 Million CHF | -31.11% |
| 2018 Q3 | -10.87 Million CHF | 17.32% |
| 2018 Q1 | -13.14 Million CHF | 19.32% |
| 2018 FY | -51.42 Million CHF | -1.91% |
| 2018 Q2 | -13.14 Million CHF | 0.0% |
| 2017 Q1 | -10.68 Million CHF | -34.21% |
| 2017 FY | -50.45 Million CHF | -52.3% |
| 2017 Q2 | -10.68 Million CHF | 0.0% |
| 2017 Q4 | -16.29 Million CHF | -27.43% |
| 2017 Q3 | -12.79 Million CHF | -19.72% |
| 2016 Q4 | -7.96 Million CHF | 0.0% |
| 2016 Q2 | -8.6 Million CHF | 0.0% |
| 2016 Q3 | -7.96 Million CHF | 7.48% |
| 2016 FY | -33.12 Million CHF | -1144.03% |
| 2016 Q1 | -8.6 Million CHF | -2.62% |
| 2015 FY | 3.17 Million CHF | 142.21% |
| 2015 Q2 | -3.1 Million CHF | 0.0% |
| 2015 Q1 | -3.1 Million CHF | -28.11% |
| 2015 Q4 | -8.38 Million CHF | 0.0% |
| 2015 Q3 | -8.38 Million CHF | -169.76% |
| 2014 Q1 | -1.54 Million CHF | -57.14% |
| 2014 FY | -7.51 Million CHF | -2.85% |
| 2014 Q2 | -1.54 Million CHF | 0.0% |
| 2014 Q4 | -2.42 Million CHF | 0.0% |
| 2014 Q3 | -2.42 Million CHF | -57.38% |
| 2013 Q1 | -2.4 Million CHF | 16.2% |
| 2013 Q4 | -981 Thousand CHF | 0.0% |
| 2013 FY | -7.3 Million CHF | 76.54% |
| 2013 Q2 | -2.4 Million CHF | 0.0% |
| 2013 Q3 | -981 Thousand CHF | 59.14% |
| 2012 Q3 | -2.86 Million CHF | 0.0% |
| 2012 FY | -31.15 Million CHF | -14.49% |
| 2012 Q4 | -2.86 Million CHF | 0.0% |
| 2011 FY | -27.21 Million CHF | -212.4% |
| 2010 FY | -8.71 Million CHF | 81.3% |
| 2009 FY | -46.59 Million CHF | -2.19% |
| 2008 FY | -45.59 Million CHF | -46.47% |
| 2007 FY | -31.12 Million CHF | -8.69% |
| 2006 FY | -28.63 Million CHF | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Relief Therapeutics Holding AG | -110.82 Million CHF | 162.118% |
| Tecan Group AG | 135.96 Million CHF | 49.367% |
| Basilea Pharmaceutica AG | 19.2 Million CHF | -258.469% |
| Bachem Holding AG | 129.38 Million CHF | 46.789% |
| Siegfried Holding AG | 172.06 Million CHF | 59.99% |
| Molecular Partners AG | -61.1 Million CHF | 212.66% |